Abstract
Paolo Spagnolo
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Unresolved referenced work
Kept as external metadata until matched
Immune checkpoint therapy—current perspectives and future directions
10.1016/j.cell.2023.03.006 · 2023
Immune-related adverse events associated with immune checkpoint blockade
10.1056/nejmra1703481 · 2018
Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
10.1200/jco.2016.68.2005 · 2017
Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis
10.1001/jamaoncol.2016.2453 · 2016
Immune checkpoint inhibitor-related pneumonitis: current advances and the putative role of mesenchymal stem cell therapy
10.1038/s41419-026-08440-7 · 2026
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · 2022
Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial
10.1093/ajrccm/aamag349 · 2026
Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis
10.3389/fimmu.2025.1656063 · 2025
Corticosteroids in oncology: use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper
10.1016/j.critrevonc.2022.103826 · 2022
Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study
10.7326/m20-1594 · 2020
No additional external references are available.